Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABVC NASDAQ:COYA NASDAQ:ENGN NASDAQ:NRXP On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVCABVC BioPharma$1.14$1.17$0.88▼$5.48$29.64M0.4278,060 shs252,700 shsCOYACoya Therapeutics$4.81$4.37$3.71▼$7.75$112.83M0.55164,062 shs75,960 shsENGNenGene$1.64$5.88$1.40▼$12.25$109.86M-0.023.78 million shs1.26 million shsNRXPNRx Pharmaceuticals$3.22$2.59$1.62▼$3.84$116.66M2.021.05 million shs1.48 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVCABVC BioPharma0.00%+6.54%+6.54%-18.57%-0.87%COYACoya Therapeutics0.00%-2.24%+11.34%-1.84%-18.47%ENGNenGene0.00%+4.46%-79.47%-83.23%-61.32%NRXPNRx Pharmaceuticals0.00%+3.21%+9.52%+71.28%+22.90%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABVCABVC BioPharma$1.14$1.17$0.88▼$5.48$29.64M0.4278,060 shs252,700 shsCOYACoya Therapeutics$4.81$4.37$3.71▼$7.75$112.83M0.55164,062 shs75,960 shsENGNenGene$1.64$5.88$1.40▼$12.25$109.86M-0.023.78 million shs1.26 million shsNRXPNRx Pharmaceuticals$3.22$2.59$1.62▼$3.84$116.66M2.021.05 million shs1.48 million shsThe Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABVCABVC BioPharma0.00%+6.54%+6.54%-18.57%-0.87%COYACoya Therapeutics0.00%-2.24%+11.34%-1.84%-18.47%ENGNenGene0.00%+4.46%-79.47%-83.23%-61.32%NRXPNRx Pharmaceuticals0.00%+3.21%+9.52%+71.28%+22.90%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABVCABVC BioPharma 1.00SellN/AN/ACOYACoya Therapeutics 2.67Moderate Buy$16.00232.64% UpsideENGNenGene 2.21Hold$12.68673.28% UpsideNRXPNRx Pharmaceuticals 2.50Moderate Buy$38.251,087.89% UpsideCurrent Analyst Ratings BreakdownLatest ABVC, COYA, ENGN, and NRXP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/15/2026ABVCABVC BioPharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/15/2026ENGNenGene Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)5/14/2026ENGNenGene UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetNeutral$9.00 ➝ $2.005/8/2026NRXPNRx Pharmaceuticals Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)5/8/2026ENGNenGene Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Outperform$4.005/8/2026ENGNenGene Piper SandlerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Neutral$7.00 ➝ $4.005/8/2026ENGNenGene CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeMarket Outperform ➝ Market Perform5/8/2026ENGNenGene Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOverweight ➝ Equal Weight$25.00 ➝ $2.005/8/2026ENGNenGene Wells Fargo & CompanySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOverweight ➝ Equal Weight$2.005/8/2026ENGNenGene Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform5/8/2026ENGNenGene Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeOutperform ➝ Market Perform$2.00(Data available from 5/26/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABVCABVC BioPharma$510K58.12N/AN/A$0.49 per share2.33COYACoya Therapeutics$7.95M14.19N/AN/A$2.09 per share2.30ENGNenGeneN/AN/AN/AN/A$2.60 per shareN/ANRXPNRx Pharmaceuticals$1.23M94.85N/AN/A($0.38) per share-8.47Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABVCABVC BioPharma-$7.91M-$0.40N/AN/AN/AN/A-62.46%-39.99%N/ACOYACoya Therapeutics-$21.23M-$1.15N/AN/AN/A-266.10%-55.86%-48.86%8/11/2026 (Estimated)ENGNenGene-$117.30M-$2.25N/AN/AN/AN/A-55.83%-45.74%6/11/2026 (Estimated)NRXPNRx Pharmaceuticals-$28.62M-$1.09N/A3.70N/AN/AN/A-202.92%N/ALatest ABVC, COYA, ENGN, and NRXP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails6/11/2026Q2 2026ENGNenGene-$0.49N/AN/AN/AN/AN/A5/18/2026Q1 2026ABVCABVC BioPharmaN/A-$0.06N/A-$0.06N/AN/A5/15/2026Q1 2026NRXPNRx Pharmaceuticals-$0.05-$0.04+$0.01-$0.04$19.43 million$1.07 million5/12/2026Q1 2026COYACoya Therapeutics-$0.39-$0.32+$0.07-$0.32$0.15 million$0.25 million3/23/2026Q4 2025NRXPNRx Pharmaceuticals-$0.09$0.19+$0.28$0.20$7.53 million$0.98 million3/16/2026Q4 2025COYACoya Therapeutics-$0.08-$0.34-$0.26-$0.34$1.93 million$3.96 million3/9/2026Q1 2026ENGNenGene-$0.55-$0.44+$0.11-$0.44N/AN/A3/3/2026Q4 2025ABVCABVC BioPharmaN/A-$0.11N/A-$0.11N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthABVCABVC BioPharmaN/AN/AN/AN/AN/ACOYACoya TherapeuticsN/AN/AN/AN/AN/AENGNenGeneN/AN/AN/AN/AN/ANRXPNRx PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABVCABVC BioPharmaN/A0.120.41COYACoya TherapeuticsN/A15.0215.02ENGNenGene0.0911.7511.75NRXPNRx PharmaceuticalsN/A0.290.31Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABVCABVC BioPharma11.38%COYACoya Therapeutics39.75%ENGNenGene64.16%NRXPNRx Pharmaceuticals4.27%Insider OwnershipCompanyInsider OwnershipABVCABVC BioPharma19.00%COYACoya Therapeutics12.00%ENGNenGene10.50%NRXPNRx Pharmaceuticals6.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABVCABVC BioPharma3026.00 million21.06 millionNot OptionableCOYACoya Therapeutics623.46 million20.64 millionNot OptionableENGNenGene3166.99 million59.95 millionN/ANRXPNRx Pharmaceuticals236.23 million33.91 millionOptionableABVC, COYA, ENGN, and NRXP HeadlinesRecent News About These CompaniesHere is why NRx Pharmaceuticals, Inc. (NRXP) is among the Best Rated Penny Stocks to Buy According to Wall Street AnalystsMay 24 at 8:31 AM | insidermonkey.comNRx Pharmaceuticals: 'Sell' On ZYESAMI/NRX-101 Failures & Depression Market UncertaintyMay 20, 2026 | seekingalpha.comNRx Pharmaceuticals Q1 Earnings Call HighlightsMay 18, 2026 | marketbeat.comNRx Pharmaceuticals Reports Q1 2026 Milestones, Including Advancements in Ketamine and NRX-101 DevelopmentMay 18, 2026 | quiverquant.comQNRx Pharmaceuticals (Nasdaq:NRXP) Reports First Quarter 2026 Financial Results and Provides Corporate UpdateMay 18, 2026 | globenewswire.comNRx Pharmaceuticals, Inc. (NRXP) Reports Q1 Loss, Lags Revenue EstimatesMay 15, 2026 | zacks.comNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report First Quarter 2026 Financial Results and Provide Corporate UpdateMay 14, 2026 | globenewswire.comNRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Clearance to Proceed with Clinical Trial of NRX-101 in Combination with Robotic-enabled Transcranial Magnetic Stimulation in ...May 7, 2026 | markets.businessinsider.comNRx Pharmaceuticals (Nasdaq:NRXP) Announces FDA Clearance to Proceed with Clinical Trial of NRX-101 in Combination with Robotic-enabled Transcranial Magnetic Stimulation in Patients with Depression and SuicidalityMay 7, 2026 | globenewswire.comNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Given Average Rating of "Moderate Buy" by BrokeragesMay 7, 2026 | marketbeat.comWhy NRx Pharmaceuticals, Inc.’s (NRXP) Stock Is Up 6.67%May 5, 2026 | aaii.comAD. Boral Capital Reaffirms Buy Rating for NRx Pharmaceuticals (NASDAQ:NRXP)May 5, 2026 | marketbeat.comNRx Pharmaceuticals (Nasdaq:NRXP) Announces Initiation of Commercial Manufacturing for Preservative Free KetamineMay 5, 2026 | globenewswire.comNRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Sees Large Growth in Short InterestApril 29, 2026 | marketbeat.comEquities Analysts Offer Predictions for NRXP Q1 EarningsApril 28, 2026 | marketbeat.comNRx Pharmaceuticals (NASDAQ:NRXP) Price Target Raised to $49.00 at Ascendiant Capital MarketsApril 27, 2026 | marketbeat.comNRx Pharmaceuticals (NASDAQ:NRXP) Earns "Buy" Rating from HC WainwrightApril 27, 2026 | marketbeat.comNRx Pharmaceuticals Reports Positive FDA Office of Generic Drugs Feedback on Preservative-Free Ketamine ProgramApril 22, 2026 | globenewswire.comNRx Pharmaceuticals (NASDAQ: NRXP) Supports Executive Order To Accelerate Psychedelic Drug DevelopmentApril 20, 2026 | theglobeandmail.comNRx Pharmaceuticals (Nasdaq:NRXP) Welcomes Presidential Initiative to Accelerate Approval of Psychedelic Medications to Treat Depression, PTSD, and SuicidalityApril 20, 2026 | globenewswire.comNRx Pharmaceuticals Advances Robotic-Enabled Transcranial Magnetic Stimulation Combined with ...April 15, 2026 | caledonianrecord.comCNew MarketBeat Followers Over TimeMedia Sentiment Over TimeABVC, COYA, ENGN, and NRXP Company DescriptionsABVC BioPharma NASDAQ:ABVC$1.14 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$1.14 0.00 (-0.44%) As of 05/22/2026 07:46 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.ABVC BioPharma, Inc., a clinical stage biopharmaceutical company, develops drugs and medical devices to fulfill unmet medical needs in the United States. The company is developing ABV-1501, which is in Phase II clinical trials a combination therapy for triple negative breast cancer; ABV-1504 has completed Phase II clinical trials for major depressive disorders; ABV-1505, which is in Phase II clinical trials for adult attention deficit hyperactivity disorder; ABV-1703, which is in Phase II clinical trials for the treatment of metastatic pancreatic cancer; ABV-1702, which is in Phase II clinical trials to treat myelodysplastic syndromes; and ABV-1601 that is in Phase I/II clinical trials for treating depression in cancer patients. It is also developing ABV-1701 Vitargus that is in Phase II clinical trials for the treatment of retinal detachment or vitreous hemorrhage; and ABV-1519, which is in Phase I/II clinical trials for the treatment of non-small cell lung cancer. ABVC BioPharma, Inc. has a co-development agreement with Rgene Corporation; and collaboration agreements with BioHopeKing Corporation and BioFirst Corporation. The company is based in Fremont, California. ABVC BioPharma, Inc. operates as a subsidiary of YuanGene Corporation.Coya Therapeutics NASDAQ:COYA$4.81 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$4.80 -0.01 (-0.21%) As of 05/22/2026 04:10 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Coya Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of proprietary medicinal products to modulate the function of regulatory T cells (Tregs). The company's product candidate pipeline is based on therapeutic modalities, such as Treg-enhancing biologics, Treg-derived exosomes, and autologous Treg cell therapy. It is developing COYA 101, an autologous regulatory T-cell product candidate that has completed Phase 2a clinical trial for use in the treatment of Amyotrophic Lateral Sclerosis. The company's product candidates in IND-enabling studies include COYA 301, a low-dose interleukin 2 Treg-enhancing biologic, which is in Phase 2 clinical trial for use in the treatment of Frontotemporal Dementia; and COYA 302, a biologic combination for subcutaneous administration intended to enhance Treg function while depleting T effector function and activated macrophages for use in the treatment of neurodegenerative and autoimmune diseases. It is also developing COYA 201, an antigen directed Treg-derived exosome product candidate that is in preclinical stage for use in the treatment of neurodegenerative, autoimmune, and metabolic diseases; and COYA 206, an antigen directed Treg-derived exosome product candidate, which is in discovery stage. The company has a collaboration with Dr. Reddy's Laboratories SA for the development and commercialization of COYA 302, an investigational combination therapy for treatment of amyotrophic lateral sclerosis. The company was incorporated in 2020 and is headquartered in Houston, Texas.enGene NASDAQ:ENGN$1.64 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$1.68 +0.04 (+2.13%) As of 05/22/2026 07:26 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.enGene Holdings Inc., through its subsidiary enGene, Inc., operates as a clinical-stage biotechnology company that develops genetic medicines through the delivery of therapeutics to mucosal tissues and other organs. Its lead product candidate is EG-70 (detalimogene voraplasmid), which is a non-viral immunotherapy to treat non-muscle invasive bladder cancer patients with carcinoma-in-situ (Cis), who are unresponsive to treatment with Bacillus Calmette-Guérin. The company was founded in 2023 and is based in Saint-Laurent, Canada.NRx Pharmaceuticals NASDAQ:NRXP$3.22 0.00 (0.00%) Closing price 05/22/2026 04:00 PM EasternExtended Trading$3.21 -0.01 (-0.31%) As of 05/22/2026 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/18 - 05/22 Ross Stores Earnings Beat Sends Stock To New Highs Was Decker’s Double Beat a Bullish Signal—Or Mere HOKA’s-Pocus? Workday Validates AI Flywheel: Stock Price Recovery Begins Apparel Earnings Winners and Losers: Ralph Lauren Takes Off SpaceX IPO: Opportunity? Or the Ultimate Hype Trade? The Careful Consumer: What Q1 Earnings Reveal—And Where Cracks May Appear Overextended, e.l.f. Beauty Is Primed to Rebound in Back Half Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
